Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis - PubMed
6 hours ago
- #breast cancer
- #ctDNA
- #prognostic biomarker
- Circulating tumor DNA (ctDNA) is a promising noninvasive biomarker for monitoring minimal residual disease (MRD) and predicting recurrence in early-stage breast cancer (EBC).
- A systematic review and meta-analysis of 18 studies (1670 patients) found ctDNA positivity significantly associated with shorter disease-free survival (DFS) (pooled HR 6.92, 95% CI 3.64-13.13; p < 0.0001).
- ctDNA positivity was a strong predictor of relapse in both neoadjuvant (HR 6.06) and adjuvant settings (HR 14.76).
- A non-significant trend was observed for worse overall survival (OS) (HR 3.91, 95% CI 0.78-19.72; p = 0.098).
- The study concludes that ctDNA positivity is a robust prognostic biomarker for recurrence in early breast cancer, suggesting its potential integration into post-treatment surveillance and interventional trials.